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 One hundred nine patients were included. 54 right breasts and 55 left 
breasts were simulated. V90% was statistically different in PP and SP 
with respectively 96.9% and 98.5% (p= 9.38E-6). PTVs max dose was 
not significantly higher in PP (PP 106.5% vs. SP 106.3%; p= 0.28) Heart 
mean dose was 2.5 % in PP and 1.6% in SP (p= 8.19E-12). Ipsilateral 
lung mean dose was significantly lower in PP (PP 2.2% vs. SP 8.6%; p= 
2.81 E-44). Percentage of ipsilateral lung receiving 20 Gy (V20Gy) was 
0.5% in PP vs. 6.8% in SP (p= 3.47E-43). 
Conclusions: PP is the best position to spare ipsilateral lung and not 
increases hot spots in the PTV. SP achieved a better coverage of the 
PTV at the expense of increased dose near skin. PP was considered 
optimal in 38 of 54 right breasts and in 26 of 55 left breasts.  
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Purpose/Objective: Pre- and posthydration during chemoradiotherapy 
of head and neck cancer administers substantial amounts of fluid 
which potentially alters the anatomy of the patient. The aim of this 
study was to determine the geometric changes of parotid glands as 
function of pre- and posthydration during chemoradiotherapy. 
Materials and Methods: A total of 38 patients were included in this 
retrospective study: 1) an experimental group (n = 19) receiving 
chemoradiotherapy, 2) a control group (n = 19) receiving radiotherapy 
only. Patients in the experimental group received cisplatin with pre- 
and posthydration during the first, fourth and seventh week of the 
treatment. For each cycle of cisplatin, 9 litres of saline solution was 
administrated intravenously to the patient. For each patient, the 
delineations of the parotid glands on the planning CT were 
automatically propagated to the daily Cone Beam CT (CBCT) scans 
through deformable image registration. Volume and position of the 
parotid glands on the CBCT scans were compared to the planning CT 
scan to calculate relative volume and position. Relative volume and 
position of the parotid glands during and after pre- and posthydration 
were compared with the start of prehydration, resulting in ΔV and ΔX 
values. The T-test with significance level α = 0.05 was used to 
compare difference between the groups. 
Results: By week six of the treatment, the mean parotid gland volume 
loss in the experimental group was 22% ± 11% (1 SD), and in the 
control group 24% ± 9%. At the same time point, the mean medial 
distance between the parotid glands decreased by 0.41 cm ± 0.20 cm 
in the experimental group and 0.51 cm ± 0.25 cm in the control group. 
No significant difference between the two groups was demonstrated 
for these general trends. 
However, when pre- and posthydration was administrated, the volume 
of the parotid glands temporarily increased and the position shifted to 
a more lateral position (figure 1). After starting prehydration (day 
zero) the relative change in volume of the parotid glands ΔV was 
significantly different between groups with 7.2% on the first day (p < 
0.001), 9.9% on the second day (p < 0.001) and 5.6% on the third day 
(p = 0.039). The relative change in position of the parotid glands ΔX 
was significantly different between groups with 1.6 mm on the first 
day (p = 0.001) and 2.0 mm on the second day (p < 0.001) after 
starting prehydration. 
 
 Conclusions: Pre- and posthydration during chemoradiotherapy has a 
significant influence on the geometry of the parotid glands. Within the 
context of adaptive radiotherapy, rescanning for replanning during 
pre- and posthydration is not advisable. 
   
OC-0351   
Volumetric modulated arc radiotherapy with flattening filter-free 
beams for advanced nasopharyngeal carcinoma 
M. Zhuang1, T. Zhang1, Z. Chen1, Z. Lin1, X. Peng1, D. Li1, Q. Qiu2, R. 
Wu3 
1Tumor Hospital of Shantou University Medical College, Radiation 
Oncology, Shantou, China  
2Shantou University Medical College, Medical Physics, Shantou, China  
3The Second Affiliated Hospital of Shantou University Medical 
College, Radiation, Shantou, China  
  
Purpose/Objective: The purpose of this study is to investigate the 
dosimetric characteristics of volumetric modulated arc radiotherapy 
(VMAT) with flattening filter-free (FFF) beams and assess the role of 
VMAT in the treatment of advanced nasopharyngeal carcinoma (NPC). 
Materials and Methods: Ten cases of CT data were randomly selected 
from advanced NPC patients. Three treatment plans were performed 
for each patient, FFF RapidArc (RA-FFF), conventional RapidArc (RA) 
and static gantry intensity modulated radiation therapy (IMRT). All of 
the plans were generated to meet the same objectives with 7000 cGy 
covering 95% of the PTV70. The doses to the planning target volumes 
(PTVs), organs at risk (OARs) and normal tissue were compared. All 
the plans were delivered on a Varian TrueBeam linear accelerator and 
verified using the Delta4 phantom. The technical delivery parameters 
including the mean gamma score, treatment delivery time and 
monitor units (MUs) were also analyzed. 
Results: All the techniques delivered adequate doses to the PTVs. 
IMRT demonstrated the highest percentage of target coverage (TC) for 
PTV60. For PTV66, RA delivered the lowest mean dose whereas IMRT 
delivered the highest mean dose. For PTV70, RA-FFF provided for 
higher maximum dose and mean dose than other techniques and gave 
the highest homogeneity index (HI). For larynx, RA delivered the 
lowest mean dose of 3183±269cGy, whereas IMRT delivered the 
highest mean dose of 3540±190cGy. For other OAR parameters, no 
significant difference among the different techniques could be 
established. Gamma analysis produced an average pass rate of 
0.985±0.010, 0.985±0.013 and 0.987±0.010 at the 3%/3mm levels for 
RA-FFF, RA and IMRT, respectively. Significant differences in the MUs 
were observed among the three techniques (p=0.000). The delivery 
time for RA-FFF and RA was 152±7s, 153±7s, respectively, which was 
reduced by nearly 70% compared to that of IMRT with the mean time 
of 493±24s.  
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Conclusions: All the treatment plans could meet the clinical therapy 
needs. The dose measurements also showed good agreement with 
computed doses. RapidArc technique can treat patients with advanced 
NPC effectively, with good target coverage and sparing of critical 
structures. RA has a slightly dosimetric superiority than RA-FFF. 
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Purpose/Objective: To quantify positional variation of the anal canal 
and inguinal lymph nodes and derive the required CTV-to-PTV 
margins. 
Materials and Methods: Ten anal cancer patients were included in 
this retrospective study, 5 male and 5 female. All patients were 
treated prone using a feet cushion to maintain a stable positioning of 
the legs over the course of treatment. In male patients, the penis and 
testicles were lifted using a scrotum holder to avoid contact between 
the target volume and these healthy tissues. Cone Beam CT scans 
were made daily prior to treatment for the first 3 fractions, and 
weekly thereafter, in the context of an offline shrinking action level 
(SAL) setup correction protocol. A total of 95 CBCT were made and 
registered to the planning CT scan.  
Setup errors were measured by evaluating the chamfer match of the 
pelvic bones. The 'organ motion' of the inguinal lymph nodes and the 
anal canal relative to the pelvic bony anatomy were measured by grey 
value registration of these structures (see figure). CTV-to-PTV margins 
were calculated based on an offline correction protocol and assuming 
a 4 mm delineation uncertainty according to: M=2.5Σ+0.7σ. 
 
  
Figure. Coronal view of the four region of interests used for 
registration; a) pelvic bones, b) inguinal lymph nodes right, c) inguinal 
lymph nodes left and d) anal tumor. 
Results: Group mean (GM), systematic error (Σ) and random error (σ) 
of the 'organ motion' of the inguinal lymph nodes and the anal canal 
are given in the table. Required CTV-to-PTV margins assuming an 
offline SAL protocol with the pelvic bones as surrogate for the 
treatment volume are also shown in the table. Margins for a pelvic 
bone online correction protocol were identical as the contribution of 
the setup error was negligible. 
 
  
Table. The Group Mean (GM), systematic error (Σ) and random error 
(σ) of the 'organ motion' of the inguinal lymph nodes right (r) and left 
(l) and the anal canal (CTV) and the margins required for an offline 
registration protocol.  
Conclusions: This study indicates that standard clinical CTV-to-PTV 
margins of 1cm and/or the registration protocol should be adjusted to 
deliver 95% of the prescribed dose to the CTV/lymph nodes for 90% of 
the patients. Adaptive radiotherapy enables compensation for the 
(differential) systematic errors of both the CTV and lymph nodes, 
allowing margins reduction.  
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What more natural than a stress response that would vary among 
individuals? The individual factor has been pointed out in numerous 
medical research areas. The idea that each individual shows a specific 
response to radiation, like face to any stress, is well-accepted by 
public, but neither taken into account into radioprotection 
recommendations nor in a systematic process of prediction in 
radiotherapy or chemotherapy. However, to date, there is much 
evidence that about 5-15% individuals are radiosensitive i.e 
susceptible to adverse tissue reactions and/or radiation-induced 
cancer. Besides, the confusion between these last two notions due to 
toxicity and cancer proneness, respectively has not facilitated the 
prediction of patients at risk. Indeed, the long quest of "the" 
predictive assay still meet technical artefacts, cell types 
specificities, lacks in the understanding of the molecular and cellular 
responses and fashion effects. The major approaches to predict 
radiosensitivity are functional assays (notably DNA repair and signaling 
pathways), gene expression assay and detection of polymorphisms 
(SNP). Considering that there is a continuum in the radio-responses 
(i.e. radiosensitivity is not an all-or-none phenomenon), it is hard to 
imaging one SNP responsible for all the radiosensitivities and one SNP 
for each radiosensitivity, inasmuch as SNP may also depend on the cell 
and tissue type. Considering that few genes show a dose-dependent 
response with the same rate as cell death or mutagenesis, it is also 
difficult to identify "the" gene expression that would predict all the 
radiosensitivity. Conversely, results of nearly 40 years of research, 
functionnal assays of repair or signalling pathways of DNA damage, 
especially DNA double-strand breaks (DSB) are promising yet because 
some quantitative correlations has been demonstrated between 
clinical, cellular and molecular features, whatever the dose.  
Unfortunately, the methodology and the endpoints that would predict 
radiosensitivity are still to be determined. Here, we propose a 
classification of radiosensitivity based on the kinetics of the radiation-
induced nucleo-shuttling of the ATM protein. 
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